Beijing Beilu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 28, 2021 at 08:05 am
Share
Beijing Beilu Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 222.075 million compared to CNY 125.780 million a year ago. Operating income was CNY 52.626 million compared to CNY 31.103 million a year ago. Net income was CNY 50.451 million compared to CNY 26.784 million a year ago. Basic earnings per share from continuing operations was CNY 0.1032 compared to CNY 0.054 a year ago. Diluted earnings per share from continuing operations was CNY 0.1144 compared to CNY 0.054 a year ago.
Beijing Beilu Pharmaceutical Co., Ltd is a China-based company principally engaged in the research, development, production and distribution of contract medium products, anti-diabetic products and anti-anxiety products. The Companyâs main products include gadopentetate dimeglumine injection, iohexol injection, Iodoparol injection, Iodixanol injection, ferric ammonium citrate effervescent granules, repaglinide tablets, glimepiride tablets, Jiuwei Zhenxin granules, among others. The Company mainly distributes its products in domestic market.